Your browser doesn't support javascript.
loading
Cerebellar tDCS as Therapy for Cerebellar Ataxias.
Maiorana, Natale; Guidetti, Matteo; Dini, Michelangelo; Priori, Alberto; Ferrucci, Roberta.
Afiliación
  • Maiorana N; "Aldo Ravelli" Center for Neurotechnology and Experimental Brain Therapeutics, Department of Health Sciences, University of Milan, Via A. di Rudinì 8, 20142, Milan, Italy.
  • Guidetti M; "Aldo Ravelli" Center for Neurotechnology and Experimental Brain Therapeutics, Department of Health Sciences, University of Milan, Via A. di Rudinì 8, 20142, Milan, Italy.
  • Dini M; Department of Electronics, Information and Bioengineering, Politecnico Di Milano, 20133, Milan, Italy.
  • Priori A; "Aldo Ravelli" Center for Neurotechnology and Experimental Brain Therapeutics, Department of Health Sciences, University of Milan, Via A. di Rudinì 8, 20142, Milan, Italy.
  • Ferrucci R; "Aldo Ravelli" Center for Neurotechnology and Experimental Brain Therapeutics, Department of Health Sciences, University of Milan, Via A. di Rudinì 8, 20142, Milan, Italy.
Cerebellum ; 21(5): 755-761, 2022 Oct.
Article en En | MEDLINE | ID: mdl-35060077
ABSTRACT
In recent years, a growing body of literature has investigated the use of non-invasive brain stimulation (NIBS) techniques to influence cerebellar activity and the effects of cerebellar stimulation on other brain regions through its multiple complex projections. From the early 1990s, with the discovery of the so-called cerebellar inhibition (CBI), several studies have focused their attention on the use of cerebellar NIBS as treatment for different motor disorders. Cerebellar ataxias (CAs) represent the prototypical clinical manifestation of cerebellar alterations, but other movement disorders, such as Parkinson's disease, essential tremor, and dystonia have also been associated with alterations of networks which include the cerebellum, or of the cerebellum itself. Cerebellar transcranial direct current stimulation (ctDCS) could indeed represent an economical, non-invasive therapeutic tool with minimal side effects, thus improving the clinical management of patients and their quality of life. Studies show that ctDCS is effective as a therapeutic option for motor symptoms in patients with CAs, and especially in those with less severe forms, suggesting that ctDCS efficacy could result from augmented neuronal compensation, which itself relies on preserved cerebellar volume. Evidence for the efficacy of ctDCS is less conclusive for the other aforementioned motor disorders, although preliminary results are promising. Future studies should adopt more rigorous methods (e.g., larger sample sizes, double blinding, better characterization of the sample, reliable biomarkers), in order to allow the scientific community to derive higher-quality evidence on the efficacy of ctDCS as a therapeutic option for motor disorders.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Ataxia Cerebelosa / Estimulación Transcraneal de Corriente Directa Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Cerebellum Asunto de la revista: CEREBRO Año: 2022 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Parkinson / Ataxia Cerebelosa / Estimulación Transcraneal de Corriente Directa Aspecto: Patient_preference Límite: Humans Idioma: En Revista: Cerebellum Asunto de la revista: CEREBRO Año: 2022 Tipo del documento: Article País de afiliación: Italia